Shire’s experimental HAE drug hits phase 3 marks

Shire is looking to its pipeline as its HAE meds come under commercial pressure

Shire has posted positive results for its late-stage hereditary angioedema candidate SHP616 against a dummy treatment.

The biopharma’s subcutaneous C1 esterase inhibitor significantly lowered hereditary angioedema (HAE) monthly attack rate against placebo in the pivotal phase 3.

Data from the Sahara test show that median HAE attack reduction hit 79% from day 0, and 85% from day 14. Shire also found that 38% of patients were HAE attack free while on its med.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its target is a rare genetic disease characterized by recurrent swelling of extremities, gastrointestinal tract and upper airways.

“Patients want and deserve options when it comes to their treatment for HAE,” said Dr. William Lumry, clinical professor of Internal Medicine at Southwestern Medical School, Dallas, Texas. “These results are clinically significant, meaningful and relevant to HAE patients whose needs are currently not met today.”

Howard Mayer, M.D., interim head of R&D at Shire, added: “We are very pleased with the strong results of this study, which demonstrated efficacy with a low volume dosing regimen, and what it potentially could mean for the global HAE community, if approved.”

Shire already sells HAE meds, but the patent expiry on one, Firazyr—used to treat acute HAE attacks—is due next year, and will put almost $600 million in sales at risk of generic erosion.

Shire is now looking to its pipeline for the next generation, and on top of SHP616, is also working on lanadelumab (a.k.a. SHP643), the kallikrein-blocking antibody it got after buying Dyax for $5.9 billion two years ago.

A few months back, that candidate cut the rate of monthly attack in patients with HAE by an impressive 87% compared to placebo in the phase 3 Help trial, setting it on track for a filing in the U.S. later this year, or in early 2018.

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.